Qingdao Baheal Medical Inc
SZSE:301015
Qingdao Baheal Medical Inc
Operating Income
Qingdao Baheal Medical Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Q
|
Qingdao Baheal Medical Inc
SZSE:301015
|
Operating Income
¥903.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
Sinopharm Group Co Ltd
HKEX:1099
|
Operating Income
¥22.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Operating Income
¥8.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Operating Income
¥4.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
17%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Operating Income
¥2.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
5%
|
CAGR 10-Years
20%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Operating Income
¥3.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
See Also
What is Qingdao Baheal Medical Inc's Operating Income?
Operating Income
903.5m
CNY
Based on the financial report for Dec 31, 2023, Qingdao Baheal Medical Inc's Operating Income amounts to 903.5m CNY.
What is Qingdao Baheal Medical Inc's Operating Income growth rate?
Operating Income CAGR 5Y
22%
Over the last year, the Operating Income growth was 24%. The average annual Operating Income growth rates for Qingdao Baheal Medical Inc have been 30% over the past three years , 22% over the past five years .